#United States #New York #Levi & Korsinsky #class action lawsuit #Actinium Pharmaceuticals

Overview of the Class Action Lawsuit Against Actinium Pharmaceuticals

Levi & Korsinsky, LLP has recently taken initiative to notify current and former investors of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) regarding a significant class action lawsuit. This legal matter aims to address purported securities fraud allegations affecting shareholders between October 31, 2022, and August 2, 2024.

What Triggered the Class Action?

The lawsuit stems from the claim that the company misled investors about its radiotherapy product Iomab-B. Allegations suggest that data from the Phase 3 Sierra trial failed to meet the necessary FDA guidelines crucial for reviewing the product's Biologics License Application (BLA). Furthermore, it is claimed that analyses presented to mitigate concerning results were baseless and unlikely to lead to FDA approval. The impact of these misleading statements has negatively affected stock prices and led to significant losses for investors.

Key Dates and Deadlines

If you are an investor who experienced losses during the specified timeframe, there is an upcoming critical date you must be aware of: May 27, 2025. This is the deadline for submitting requests to become the lead plaintiff in this case. Although taking on this role is not a prerequisite to share in any recovery, your participation as a class member could entitle you to compensation without incurring any direct costs.

No Cost Participation

Actinium investors should note that their eligibility for compensation will not require any out-of-pocket fees or expenses. This is a significant point, as many investors may hesitate to engage in legal proceedings due to perceived costs. By participating in this class action, stakeholders have the opportunity to seek justice and possible restitution at no financial risk to themselves.

Reasons Behind the Lawsuit

The defendants in this case are accused of making multiple false statements and concealing critical details regarding the viability of the Iomab-B product. The main points raised in the lawsuit include:
1. The data presented from the Sierra trial is unlikely to meet FDA standards necessary for the approval of Iomab-B.
2. The extended analyses shared with the FDA supposedly demonstrating improved Overall Survival metrics are not supported by factual evidence.
3. There is a strong possibility that the FDA will either deny to review the application or reject it outright, should they choose to review it.
4. The repeated positive portrayals made by the company regarding its operations and future prospects lacked a solid foundation and could potentially mislead stakeholders.

Why Choose Levi & Korsinsky?

Levi & Korsinsky comes with a notable track record, having spent over 20 years in the field of securities litigation. Their commitment to safeguarding shareholder rights has led to recoveries amounting to hundreds of millions of dollars. Among the top securities litigation firms in the U.S., they have consistently ranked in ISS Securities Class Action Services' Top 50 Report for seven consecutive years. Their experienced team of legal professionals is well-equipped to guide clients through this complex situation.

Contact Information

Those who believe they qualify for this class action lawsuit or simply wish to learn more about the process can reach out to Levi & Korsinsky. Investors may contact Joseph E. Levi, Esq. directly through his email or by phone at (212) 363-7500. Additionally, detailed information can be found on their website, where potential class members can fill out a submission form for more guidance on the next steps.

To secure your place as a class member and explore your options in this lawsuit, don’t delay. The deadline is approaching, and time is of the essence for all Actinium investors affected by this situation.